Condition: Endometrial Cancer · Sponsor: William Bradley
This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy. The goal is to see how well the drug works and how safe it is. Patients will be treated for up to one year and followed over time to monitor their health and response to the treatment.
This description comes directly from the study's public registry record.
Mastaneh Irani · 4148056621 · mairani@mcw.edu
Sukanya Skandarajah, Research Operations Manager · 4148055337 · sskandarajah@mcw.edu
Always discuss trial participation with your own doctor first.
| Froedtert Memorial Lutheran Hospital | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07139977